Lucile Astorgues‐Xerri

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition

Anton G. Henssen, Kristina Althoff, Andrea Odersky et al. · Clinical Cancer Research · 2015 · 180 citations · Full text

Medicine, Cancer Biology, Oncology +12

OTX015 (MK‐8628), a novel BET inhibitor, displays <i>in vitro</i> and <i>in vivo</i> antitumor effects alone and in combination with conventional therapies in glioblastoma models

Caroline Berenguer‐Daizé, Lucile Astorgues‐Xerri, Elodie Odore et al. · International Journal of Cancer · 2016 · 151 citations · Full text

Medicine, Oncology, Pharmacology +14

OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis

Lucile Astorgues‐Xerri, María E. Riveiro, Annemilaï Tijeras‐Raballand et al. · European Journal of Cancer · 2014 · 137 citations · Full text

Medicine, Oncology, Pharmacology +14

Antitumor Agent Calixarene 0118 Targets Human Galectin-1 as an Allosteric Inhibitor of Carbohydrate Binding

Ruud P.M. Dings, Michelle C. Miller, Irina V. Nesmelova et al. · Journal of Medicinal Chemistry · 2012 · 133 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus

Ramiro Vázquez, María E. Riveiro, Lucile Astorgues‐Xerri et al. · Oncotarget · 2016 · 92 citations · Full text

Medicine, Oncology, Pharmacology +13